Veteran of J&J’s M&A Group to bring additional partnership generation and financial sourcing skills to Board
TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm” or the “Company”), a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, today announced the appointment of Ms. Margaret (Meg) Helms as the newest member of the Company’s Board of Directors (“BOD”).
Ms. Helms is a veteran mergers and acquisitions (“M&A”) professional with over 25 years of executive level experience in business transactions. These include publicly traded and privately held acquisitions, divestitures, equity investments and IP licensing, as well as distribution, supply and co-promotion agreements. Her deals have spanned the globe, including China, Israel, Mexico and the EU. Meg’s extensive track record of completed global transactions includes medical devices, pharmaceuticals, biologics and health information technologies.
As the President and Founder of Morgan Wallace Associates, a global strategic healthcare M&A consulting firm focused on small to mid-cap companies, Ms. Helms works with private equity firms, medical start-up companies and medical device inventors who are seeking licensees and/or strategic partners. Prior to Morgan Wallace Associates, Meg spent 31 years with Johnson & Johnson (“J&”J). During this time, she was responsible for new business development, closing dozens of M&A transactions and contributing to a cumulative Business Unit revenue growth of over $500 million. She is particularly skilled at handling complex global acquisitions, most recently in Israel and China.
Ms. Helms holds an MBA from Washington University – St. Louis, and a BA from Rutgers University (Douglas College), New Brunswick, NJ. She is a member of the professional Licensing Executives Society (LES), the Healthcare Businesswomen’s Association (HBA), Women’s Business Leaders in Healthcare (WBL). Meg is also very active in community service and not-for-profit organizations.
Ms. Helms’ addition to the BOD was accomplished by a voluntary change in roles. Ms. Helms takes the board seat that was intended for Dr. David Armstrong, who will remain active as a member of the Company’s Advisory Board, and focus on identifying global investors for CardioComm.
Ms. Helms’ addition to the BOD caps a busy Q3 at the executive management and board levels, which included the addition of Dr. David Armstrong and Dr. Robin Black to the Advisory Board, the selection of John Overall to the position of CFO, and the appointment of Robert Caines, Founding Partner of Paley Advisors, to the position of Chairman of the Board.
These executive and board-level changes have occurred as the Company’s fiscal performance has significantly improved. As stated in the Company’s Q3 Management’s Discussion and Analysis (MD&A), published this week on SEDAR, CardioComm is reporting a profitable Q3. The Company’s immediate priority is the retirement of its current line of credit, due at the end of December 2016. The Company has entered into financing discussions with several investors, seeking to retire the line of credit through new debt placement or a combination of a debt facility and equity.
In tandem with its efforts to retire the current line of credit, the BOD continues to focus on sourcing long-term financing for closing potential bolt-on acquisitions and closing several joint venture deals in 2017 that will expand operational capacities and stimulate sales of the Company’s Global ECG Management Software (GEMS™ WIN), handheld HeartCheck™ ECG devices and SMART Monitoring ECG services.
To learn more about CardioComm Solutions please see the Company’s websites www.theheartcheck.com and www.cardiocommsolutions.com or contact the Company at sales@cardiocommsolutions.com.
